SA
Log In
PCRX
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Hold
32 analysts·High coverage
59
Score
15 Buy (47%)13 Hold (41%)4 Sell (12%)
Rating Breakdown
Strong Buy
00%
Buy
1547%
Hold
1341%
Sell
413%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$27.00
+9.4%
Consensus
$29.50
+19.5%
Bull
$32.00
+29.6%
12-Month Target Range32 analysts
$27.00$29.50$32.00
Current $24.69Consensus
Current Price
$24.69
Upside to Consensus
$4.81

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+8.36%
EPS+25.48%
FY2028
Rev+14.91%
EPS+35.69%
FY2029
Rev-3.08%
EPS+0.82%

Earnings Surprises

Recent Analyst Actions

May 1, 2026Needham
Pacira price target raised to $32 from $30 at Needham
Target:$32.00
+25.5%from $25.49
Dec 8, 2025Barclays
Pacira initiated with an Equal Weight at Barclays
Target:$27.00
+10.6%from $24.42
Feb 28, 2025Barclays
Pacira price target raised to $24 from $17 at Barclays
Target:$24.00
-0.2%from $24.05
Feb 28, 2025H.C. Wainwright
Pacira price target raised to $48 from $39 at H.C. Wainwright
Target:$48.00
+99.6%from $24.05
Jan 30, 2025Truist Financial
Truist Securities Upgrades Pacira Pharmaceuticals (PCRX) to Buy
Target:$25.00
-4.0%from $26.03
Nov 7, 2024Piper Sandler
Pacira Pharmaceuticals (PCRX) PT Raised to $12 at Piper Sandler
Target:$12.00
-30.9%from $17.36
Sep 24, 2024Jefferies
Pacira Pharmaceuticals (PCRX) PT Raised to $18 at Jefferies
Target:$18.00
+21.9%from $14.77
Aug 13, 2024Truist Financial
Pacira downgraded to Sell from Buy at Truist
Target:$8.00
-34.9%from $12.29
Jul 2, 2024H.C. Wainwright
Pacira should be bought on today's selloff, says H.C. Wainwright
Target:$57.00
+160.2%from $21.91
Jun 13, 2024Jefferies
Jefferies Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)
Target:$36.00
+26.3%from $28.50
May 21, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Pacira Pharmaceuticals (PCRX)
Target:$42.00
+36.9%from $30.68
Jan 6, 2023BMO Capital
BMO Capital Maintains Market Perform on Pacira BioSciences, Lowers Price Target to $52
Target:$52.00
+35.1%from $38.50
Jan 6, 2023Needham
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $63
Target:$63.00
+63.6%from $38.50

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance